Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
October 01, 2024 02:04 ET | Nxera Pharma
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
October 01, 2024 02:02 ET | Nxera Pharma
QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
September 24, 2024 02:06 ET | Nxera Pharma
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
September 13, 2024 02:30 ET | Nxera Pharma
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesCancer Research UK’s Centre for...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
September 11, 2024 06:52 ET | Nxera Pharma
ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency and had a favorable safety and tolerability profile with no observations of frequently reported...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
September 01, 2024 19:30 ET | Nxera Pharma
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
August 28, 2024 07:07 ET | Nxera Pharma
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
August 09, 2024 02:30 ET | Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
July 09, 2024 07:14 ET | Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on...
Nxera+Master+Logo+RGB+Black+(1).png
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
June 26, 2024 19:05 ET | Nxera Pharma
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...